Search Results - "Blom, Dirk J"

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events by Sabatine, Marc S, Giugliano, Robert P, Wiviott, Stephen D, Raal, Frederick J, Blom, Dirk J, Robinson, Jennifer, Ballantyne, Christie M, Somaratne, Ransi, Legg, Jason, Wasserman, Scott M, Scott, Robert, Koren, Michael J, Stein, Evan A

“…In two randomized trials, evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9), reduced LDL cholesterol levels…”
Get full text

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial by Raal, Frederick J, Prof, Honarpour, Narimon, MD, Blom, Dirk J, MD, Hovingh, G Kees, MD, Xu, Feng, MS, Scott, Rob, MD, Wasserman, Scott M, MD, Stein, Evan A, Prof

“…Summary Background Homozygous familial hypercholesterolaemia is a rare, serious disorder caused by very low or absent plasma clearance of LDL, substantially…”
Get full text

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia by Blom, Dirk J, Hala, Tomas, Bolognese, Michael, Lillestol, Michael J, Toth, Phillip D, Burgess, Lesley, Ceska, Richard, Roth, Eli, Koren, Michael J, Ballantyne, Christie M, Monsalvo, Maria Laura, Tsirtsonis, Kate, Kim, Jae B, Scott, Rob, Wasserman, Scott M, Stein, Evan A

“…Patients with hyperlipidemia were assigned to receive the PCSK9 antibody evolocumab or placebo on a background of lipid-lowering therapy. At 52 weeks, the…”
Get full text

Letter in Response to "Lomitapide: A Medication Use Evaluation and a Formulary Perspective" by Esba and Alharbi by Blom, Dirk J

Get full text

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia by Watts, Gerald F., Gidding, Samuel S., Hegele, Robert A., Raal, Frederick J., Sturm, Amy C., Jones, Laney K., Sarkies, Mitchell N., Al-Rasadi, Khalid, Blom, Dirk J., Daccord, Magdalena, de Ferranti, Sarah D., Folco, Emanuela, Libby, Peter, Mata, Pedro, Nawawi, Hapizah M., Ramaswami, Uma, Ray, Kausik K., Stefanutti, Claudia, Yamashita, Shizuya, Pang, Jing, Thompson, Gilbert R., Santos, Raul D.

“…This contemporary, international, evidence-informed guidance aims to achieve the greatest good for the greatest number of people with familial…”
Get full text

Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies by Botha, Theunis C., Pilcher, Gillian J., Wolmarans, Karen, Blom, Dirk J., Raal, Frederick J.

“…Pregnancy in HoFH females is associated with further elevation of already markedly elevated low density lipoprotein cholesterol (LDL-C) levels, particularly if…”
Get full text

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study by Cuchel, Marina, Dr, Meagher, Emma A, MD, du Toit Theron, Hendrik, Prof, Blom, Dirk J, PhD, Marais, A David, Prof, Hegele, Robert A, Prof, Averna, Maurizio R, Prof, Sirtori, Cesare R, Prof, Shah, Prediman K, Prof, Gaudet, Daniel, MD, Stefanutti, Claudia, MD, Vigna, Giovanni B, MD, Du Plessis, Anna ME, MMed, Propert, Kathleen J, Prof, Sasiela, William J, PhD, Bloedon, LeAnne T, MS, Rader, Daniel J, Prof

“…Summary Background Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety…”
Get full text

Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis by Blom, Dirk J., Raal, Frederick J., Santos, Raul D., Marais, A. David

“…Purpose of Review The goal of this review is to evaluate the role of inhibiting the synthesis of lipoproteins when there is no or little residual LDL-receptor…”
Get full text

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial by Raal, Frederick J, Prof, Santos, Raul D, MD, Blom, Dirk J, MD, Marais, A David, Prof, Charng, Min-Ji, MD, Cromwell, William C, MD, Lachmann, Robin H, MRCP, Gaudet, Daniel, MD, Tan, Ju L, MB BS, Chasan-Taber, Scott, PhD, Tribble, Diane L, PhD, Flaim, JoAnn D, PhD, Crooke, Stanley T, MD

“…Summary Background Homozygous familial hypercholesterolaemia is a rare genetic disorder in which both LDL-receptor alleles are defective, resulting in very…”
Get full text

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia by Blom, Dirk J, Cuchel, Marina, Ager, Miranda, Phillips, Helen

“…Homozygous familial hypercholesterolaemia (HoFH) is characterized by a markedly increased risk of premature cardiovascular (CV) events and cardiac death…”
Get full text

Effect of Evolocumab on Lipoprotein Particles by Toth, Peter P., Sattar, Naveed, Blom, Dirk J., Martin, Seth S., Jones, Steven R., Monsalvo, Maria Laura, Elliott, Mary, Davis, Mike, Somaratne, Ransi, Preiss, David

“…The level of low-density lipoprotein cholesterol (LDL-C) reflects the cholesterol carried mainly by low-density lipoprotein particles (LDL-P). LDL-C, however,…”
Get full text

Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome by Blom, Dirk J., Koren, Michael J., Roth, Eli, Monsalvo, Maria Laura, Djedjos, C. Stephen, Nelson, Patric, Elliott, Mary, Wasserman, Scott M., Ballantyne, Christie M., Holman, Rury R.

“…Aim To examine the lipid and glycaemic effects of 52 weeks of treatment with evolocumab. Materials and Methods The Durable Effect of PCSK9 Antibody Compared…”
Get full text

Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects by Lambert, Gilles, PhD, Petrides, Francine, BSc, Chatelais, Mathias, BSc, Blom, Dirk J., MD, PhD, Choque, Benjamin, PhD, Tabet, Fatiha, PhD, Wong, Gida, MD, Rye, Kerry-Anne, PhD, Hooper, Amanda J., PhD, Burnett, John R., MD, PhD, Barter, Philip J., MD, PhD, Marais, A. David, MD

“…Objectives Do elevated proprotein convertase subtilisin/kexin type 9 (PCSK9) levels constitute an even greater risk for patients who already have reduced…”
Get full text

Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab by Lambert, Gilles, PhD, Chatelais, Mathias, BSc, Petrides, Francine, BSc, Passard, Maxime, BSc, Thedrez, Aurélie, PhD, Rye, Kerry-Anne, PhD, Schwahn, Uwe, PhD, Gusarova, Viktoria, PhD, Blom, Dirk J., MD, PhD, Sasiela, William, PhD, Marais, A. David, MD

“…Proprotein convertase subtilisin kexin type-9 (PCSK9) inhibition using monoclonal antibodies (mAbs) lowers low-density lipoprotein cholesterol (LDL-C) by >50%…”
Get full text

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design by Blom, Dirk J., MD, PhD, Fayad, Zahi A., BSEE, MSE, PhD, Kastelein, John J.P., MD, PhD, Larrey, Dominique, MD, PhD, Makris, Lukas, BS, MS, PhD, Schwamlein, Charles, MD, MPH, Bloeden, LeAnne, BS, MS, RD, Underberg, James, MS, MD

“…Background Lomitapide is an orally active selective inhibitor of microsomal triglyceride transfer protein approved as adjunctive therapy for homozygous…”
Get full text

Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes by Blom, Dirk J., Chen, Jiyan, Yuan, Zuyi, Borges, Joao L. C., Monsalvo, Maria L., Wang, Nan, Hamer, Andrew W., Ge, Junbo

“…Aims We assessed the change from baseline in vitamin E, steroid hormones, adrenocorticotropic hormone (ACTH), and gonadotropins, overall and by lowest achieved…”
Get full text

Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia by Blanchard, Valentin, BS, Croyal, Mikaël, PhD, Khantalin, Ilya, MD, Ramin-Mangata, Stéphane, BS, Chemello, Kévin, BS, Nativel, Brice, PhD, Blom, Dirk. J., MD, PhD, Marais, A. David, MD, Lambert, Gilles, PhD

“…There are 3 isoforms of apolipoprotein E (apo E) in humans (ε2, ε3, and ε4). They differ by single amino acid substitutions that variably affect their affinity…”
Get full text

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk by Das Pradhan, Aruna, Glynn, Robert J., Fruchart, Jean-Charles, MacFadyen, Jean G., Zaharris, Elaine S., Everett, Brendan M., Campbell, Stuart E., Oshima, Ryu, Amarenco, Pierre, Blom, Dirk J., Brinton, Eliot A., Eckel, Robert H., Elam, Marshall B., Felicio, João S., Ginsberg, Henry N., Goudev, Assen, Ishibashi, Shun, Joseph, Jacob, Kodama, Tatsuhiko, Koenig, Wolfgang, Leiter, Lawrence A., Lorenzatti, Alberto J., Mankovsky, Boris, Marx, Nikolaus, Nordestgaard, Børge G., Páll, Dénes, Ray, Kausik K., Santos, Raul D., Soran, Handrean, Susekov, Andrey, Tendera, Michal, Yokote, Koutaro, Paynter, Nina P., Buring, Julie E., Libby, Peter, Ridker, Paul M

“…In a randomized trial, patients with type 2 diabetes, hypertriglyceridemia, and low HDL cholesterol who received pemafibrate did not have fewer cardiovascular…”
Get full text

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia by Santos, Raul D., Stein, Evan A., Hovingh, G. Kees, Blom, Dirk J., Soran, Handrean, Watts, Gerald F., López, J. Antonio G., Bray, Sarah, Kurtz, Christopher E., Hamer, Andrew W., Raal, Frederick J.

“…Proprotein convertase subtilisin/kexin type 9 inhibitor therapy is a treatment option for patients with familial hypercholesterolemia (FH) who are unable to…”
Get full text

A report card for healthy aging in South Africa by Blom, Dirk J

Get full text